← Leaderboards
Daniel A Wettstein
Navigen, Inc.
$1,649,973
Attributed
$3,299,945
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$3,299,945 · 2
By mechanism
SB1$3,000,000 · 1
R43$299,945 · 1
Top collaborators
- Alan L Mueller3 shared
- James Nicholas Francis1 shared
Most similar at Navigen, Inc.
Same institution · by research overlap
- Alan L Mueller$15,252,253
- Brett D Welch$8,974,527
- James Nicholas Francis$149,973
Others in their field
Other Emerging Leaders on “Binding”
- Xinhua Li · Nano Terra, Inc.$35,520,438
- John Damon Chodera · Sloan-Kettering Inst Can Research$21,305,909
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Kristian Graugaard Andersen · Scripps Research Institute, The$18,732,618
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
BindingImmunogenicityPenetrationToxicologyCellsHiv Entry InhibitorsInhibitor/AntagonistIn VivoPropertyAffinityPeptidesPeptide HydrolasesAmino AcidsClinical DevelopmentAgreementClinical TrialsAnimalsAcquired Immunodeficiency SyndromeCombined Modality TherapyConsultAnimal EfficacyCessation Of LifeAcuteAward
Grant awards (4)
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2019 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2018 · AI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2017 · AI
D-peptide inhibitors of SIRPα anti-phagocytic signaling$299,945
R43 · FY2017 · CA · contact PI